Category : Search result: The Derma Co revenue


Honasa Consumer Q2 Profit Hits ₹39 Crore

Honasa Consumer reports strong Q2 FY26 results with ₹39.23 crore profit and 16.5% revenue growth. Mamaearth and The Derma Co drive 75% of revenues. Read full analysis.

Enrique Iglesias Mumbai Concert Draws 60,000 Fans

Enrique Iglesias made a spectacular return to India with sold-out Mumbai concerts after 13 years, drawing over 60,000 fans and generating $10 million in tourism revenue. Relive the epic musical celebration!

HT Media Q2 Loss Narrows to ₹4.34 Crore

HT Media Ltd reduces quarterly loss to ₹4.34 crore while revenue grows to ₹451.50 crore. Print and digital segments show strong growth despite radio challenges. Read full analysis.

Subex Q2 FY26: Revenue Rises, Profit Declines 78%

Subex Limited reports mixed Q2 FY26 results with revenue growth of 3.78% YoY to ₹6,891 lakhs but profit after tax plunges 78%. Normalized EBITDA shows operational improvement. Read full analysis.

DESCO Infratech Strong H1 FY2025 Results

DESCO Infratech Limited announces impressive financial performance for H1 FY2025, reporting significant revenue growth and profitability while reaffirming strong projections for H2.

GST Revenue Sharing Formula to Change in 2026

A major shift in how GST revenue is distributed among Indian states is on the horizon. Discover which states stand to gain or lose billions and how this could reshape fiscal federalism.

Hexaware Q3 Revenue $394.8M, Up 5.5% YoY

Hexaware Technologies reports impressive Q3 CY25 results with $394.8 million revenue, marking 5.5% year-over-year growth. Discover the key drivers behind this performance and what's next for the IT major.

Server glitch disrupts RI exam in Odisha

A server malfunction during the Revenue Inspector examination in Odisha caused temporary disruption, affecting thousands of aspirants across multiple exam centers.

AstraZeneca Q3 Profit Jumps 77% to $2.53 Billion

British-Swedish pharma giant AstraZeneca reports blockbuster Q3 results with profits surging 77% to $2.53 billion, driven by robust cancer drug sales and strategic US market expansion.

Page 1 of 4